Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response a review of the literature

Thrombosis and Haemostasis

Volumn 116, Issue 4, 2016, Pages 638-650

  Le Quellec, Sandra ^a   Bordet, Jean Claude ^a   Negrier, Claude ^a   Dargaud, Yesim ^a  

^a HOSPICES CIVILS DE LYON   (France)

Author keywords

Aggregometry; Antiplatelet agents; Aspirin resistance; Clopidogrel resistance; Platelet function test

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

AGGREGOMETRY; AREA UNDER THE CURVE; ASSESSMENT OF HUMANS; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; POINT OF CARE TESTING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION ANALYZER; THROMBOELASTOGRAPHY; ANALOGS AND DERIVATIVES; DRUG EFFECTS; THROMBOCYTE;

ASPIRIN; BLOOD PLATELETS; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TICLOPIDINE;

EID: 84989186785     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-11-0870     Document Type: Review

References (129)

1. FitzGerald GA, et al. Presystemic acetylation of platelets by aspirin: reduction in rate of drug delivery to improve biochemical selectivity for thromboxane A2. J Pharmacol Exp Ther 1991; 259: 1043–1049.
2. Gong IY, et al. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Eur Heart J 2012; 33: 2856–2864a.
3. Kim KA, et al. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008; 84: 236–242.
4. Trenk D, Kristensen SD, Hochholzer W, et al. High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials: Thromb Haemost 2012; 109: 834–845.
5. Ding Z, Kim S, Dorsam RT, et al. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 2003; 101: 3908–3914.
6. De Miguel A, et al. Clinical implications of clopidogrel resistance. Thromb Haemost 2008; 100: 196–203.
7. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007; 115: 2196–2207.
8. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180–186.
9. Thebault JJ, et al. Single-dose pharmacodynamics of clopidogrel. Semin Thromb Hemost 1999; 25 (Suppl 2): 3–8.
10. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606–617.
11. Gasparyan AY, et al. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51: 1829–1843.
12. Gum PA, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230–235.
13. Tantry US, et al. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46: 1705–1709.
14. Mani H, et al. Response to aspirin and clopidogrel monitored with different platelet function methods. Platelets 2006; 17: 303–310.
15. Nguyen TA, et al. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005; 45: 1157–1164.
16. Gurbel PA, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908–2913.
17. Järemo P, et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252: 233–238.
18. Müller I, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783–787.
19. Serebruany VL, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246–251.
20. Gorog DA, et al. Antiplatelet drug “resistance”. Part 2: laboratory resistance to antiplatelet drugs–fact or artifact? Nat Rev Cardiol 2009; 6: 365–373.
21. Maree AO, et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3: 2340–2345.
22. Born GV, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178–195.
23. Breddin HK. Can platelet aggregometry be standardized? Platelets 2005; 16: 151–158.
24. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000; 111: 733–744.
25. Scarborough RM. Development of eptifibatide. Am Heart J 1999; 138: 1093–1104.
26. Patel P, et al. Impact of adenosine diphosphate and calcium chelation on platelet aggregation testing in patients receiving clopidogrel therapy. J Am Coll Cardiol 2006; 47: 464–465.
27. Merolla M, et al. Centrifugation speed affects light transmission aggregometry. Int J Lab Hematol 2012; 34: 81–85.
28. Mani H, et al. Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements. J Clin Pathol 2005; 58: 747–750.
29. Van der Stelt CAK, et al. To adjust or not to adjust the platelet count in light transmission aggregometry in patients receiving dual aspirin/clopidogrel treatment. Platelets 2007; 18: 550–553.
30. Linnemann B, et al. Standardisation of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost 2008; 6: 677–683.
31. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004; 110: e489–493.
32. Nicholson NS, et al. Assessment of platelet function assays. Am Heart J 1998; 135 (Suppl 2): S170–178.
33. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980–1987.
34. Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 379–390.
35. Madsen EH, et al. Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. Platelets 2008; 19: 335–341.
36. Madsen EH, et al. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin Chem 2010; 56: 839–847.
37. Karon BS, et al. Precision and Reliability of 5 Platelet Function Tests in Healthy Volunteers and Donors on Daily Antiplatelet Agent Therapy. Clin Chem 2014; 60: 1524–1531.
38. Gachet C, et al. The platelet P2 receptors in arterial thrombosis. Blood Cells Mol Dis 2006; 36: 223–227.
39. Gurbel PA, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822–1834.
40. Angiolillo DJ, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505–1516.
41. Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res 2007; 120: 311–321.
42. Gurbel PA, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820–1826.
43. Labarthe B, et al. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 2005; 46: 638–645.
44. Van Werkum JW, et al. Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation? J Thromb Haemost 2007; 5: 884–886.
45. Marcucci R, et al. Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thromb Haemost 2007; 98: 844–851.
46. Lordkipanidzé M, et al. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel. Thromb Res 2009; 124: 546–553.
47. Meen Ø, et al. Variability in aggregometry response before and after initiation of clopidogrel therapy. Scand J Clin Lab Invest 2009; 69: 673–679.
48. Lordkipanidzé M, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702–1708.
49. Pedersen SB, et al. Evaluation of aspirin response by Multiplate whole blood aggregometry and light transmission aggregometry. Platelets 2009; 20: 415–420.
50. Nielsen HL, et al. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thromb Res 2008; 123: 267–273.
51. Harrison P, et al. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 2008; 19: 119–124.
52. Santilli F, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resis-tance.”J Am Coll Cardiol 2009; 53: 667–677.
53. Liang Y, et al. Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin. J Thromb Thrombolysis 2012; 34: 429–436.
54. Gaglia MA, et al. Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention. J Intervent Cardiol 2011; 24: 529–534.
55. Gremmel T, et al. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. Thromb Res 2011; 128: 352–357.
56. Linnemann B, et al. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. Ann Hematol 2010; 89: 597–605.
57. Tsantes A, et al. Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance. Platelets 2012; 23: 481–489.
58. Kim I-S, et al. Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading. Am Heart J 2013; 166: 95–103.
59. Bagoly Z, et al. Comparison of a New P2Y12 Receptor Specific Platelet Aggregation Test with Other Laboratory Methods in Stroke Patients on Clopidogrel Monotherapy. PLoS ONE 2013; 8: e69417.
60. Blais N, et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb Haemost 2009; 102: 404–411.
61. Varenhorst C, et al. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coad-ministered with aspirin. Am Heart J 2009; 157: 562.e1–9.
62. Bidet A, et al. VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation. Platelets 2010; 21: 94–100.
63. Hochholzer W, et al. Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel. Thromb Res 2007; 119: 285–291.
64. Dyszkiewicz-Korpanty A, et al. Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyser (PFA-100). Platelets 2007; 18: 491–496.
65. Bouman HJ, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010; 8: 482–488.
66. Tóth O, et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781–788.
67. Mueller T, et al. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyser--comparison with two flow cytometric methods. Thromb Res 2007; 121: 249–258.
68. Sibbing D, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849–856.
69. Dyszkiewicz-Korpanty AM, et al. Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods. Clin Appl Thromb Off J Int Acad Clin Appl Thromb 2005; 11: 25–35.
70. McGlasson DL, Fritsma GA. Whole blood platelet aggregometry and platelet function testing. Semin Thromb Hemost 2009; 35: 168–180.
71. Riess H, et al. Critical evaluation of platelet aggregation in whole human blood. Am J Clin Pathol 1986; 85: 50–56.
72. Sibbing D, et al. Pharmacokinetics of clopidogrel in patients with stent thrombosis. J Thromb Haemost 2008; 6: 1230–1232.
73. Paniccia R, et al. Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol 2009; 131: 834–842.
74. Amann M, et al. Validation of a P2Y12-receptor specific whole blood platelet aggregation assay. Platelets 2016; Epub ahead of print.
75. Coleman A, et al. Determination of Individual Response to Aspirin Therapy Using the Accumetrics Ultegra RFPA-ASA System. Point of Care 2004; 3: 77–82.
76. Rand ML, et al. Platelet function assays. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis 2003; 28: 307–317.
77. Harrison P, et al. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke J Cereb Circ 2005; 36: 1001–1005.
78. Lee P-Y, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005; 118: 723–727.
79. Malinin A, et al. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyser. Blood Coagul Fibrinolysis Int J Haemost Thromb 2004; 15: 295–301.
80. Dyszkiewicz-Korpanty AM, et al. Comparison of a rapid platelet function assay--Verify Now Aspirin--with whole blood impedance aggregometry for the detection of aspirin resistance. Thromb Res 2007; 120: 485–488.
81. Karha J, et al. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J 2006; 151: 976.e7–11.
82. Paniccia R, et al. Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. Am J Clin Pathol 2007; 128: 143–149.
83. Sumaya W, et al. Hirudin anticoagulation allows more rapid determination of P2Y12 inhibition by the VerifyNow P2Y12 assay. Thromb Haemost 2013; 109: 550–555.
84. Kaiser AFC, et al. Which is the best anticoagulant for whole blood aggregometry platelet function testing? Comparison of six anticoagulants and diverse storage conditions. Platelets 2012; 23: 359–367.
85. Van Werkum JW, et al. The flow cytometric VASP assay can be used to determine the effectiveness of clopidogrel in patients treated with abciximab. J Thromb Haemost 2007; 5: 881–883.
86. Paniccia R, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5: 1839–1847.
87. Malinin A, et al. Monitoring platelet inhibition after clopidogrel with the Ver-ifyNow-P2Y12(R) rapid analyser: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007; 119: 277–284.
88. Jilma B. Platelet function analyser (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138: 152–163.
89. Homoncik M, et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyser PFA-100. Thromb Haemost 2000; 83: 316–321.
90. Feuring M, et al. Monitoring acetylsalicylic acid effects with the platelet function analyser PFA-100. Semin Thromb Hemost 2005; 31: 411–415.
91. Klein Gunnewiek JMT, et al. The influence of acetylsalicylic acid intake by healthy volunteers on duplicate PFA-100 measurements. Blood Coagul Fibrinolysis Int J Haemost Thromb 2005; 16: 337–340.
92. Mortensen J, et al. Monitoring aspirin therapy with the Platelet Function Analyser-100. Scand J Clin Lab Invest 2008; 68: 786–792.
93. Agarwal S, et al. Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyser (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry. Anesthesiology 2006; 105: 676–683.
94. Alström U, et al. The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment. Thromb Res 2007; 120: 353–359.
95. Geiger J, et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005; 51: 957–965.
96. Kotzailias N, et al. Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyser-100 system in stroke patients. J Stroke Cer-ebrovasc Dis Off J Natl Stroke Assoc 2007; 16: 199–202.
97. Golanski J, et al. Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists--in vitro experience. Clin Chem Lab Med CCLM FESCC 2004; 42: 25–29.
98. Bochsen L, et al. Evaluation of the TEG platelet mapping assay in blood donors. Thromb J 2007; 5: 3.
99. Craft RM, et al. A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004; 143: 301–309.
100. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005; 27: 81–90.
101. Lang T, et al. Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis Int J Haemost Thromb 2005; 16: 301–310.
102. Hobson AR, et al. A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography. Platelets 2007; 18: 497–505.
103. Swallow RA, et al. Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy? Platelets 2006; 17: 385–392.
104. Hobson AR, et al. Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy. Thromb J 2008; 6: 1.
105. Hobson A, Curzen N. Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting. Thromb Haemost 2009; 101: 23–30.
106. Hobson AR, et al. Gender and responses to aspirin and clopidogrel: insights using short thrombelastography. Cardiovasc Ther 2009; 27: 246–252.
107. Cotton JM, et al. Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography? Cardiovasc Ther 2010; 28: 139–146.
108. Sambu N, et al. “Short” thrombelastography as a test of platelet reactivity in response to antiplatelet therapy: validation and reproducibility. Platelets 2011; 22: 210–216.
109. Hübl W, et al. Assessing aspirin-induced attenuation of platelet reactivity by flow cytometry. Thromb Res 2007; 121: 135–143.
110. Gurbel PA, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827–1832.
111. Schwarz UR, et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999; 82: 1145–1152.
112. Horstrup K, et al. Phosphorylation of Focal Adhesion Vasodilator-Stimulated Phosphoprotein at Ser157 in Intact Human Platelets Correlates with Fibri-nogen Receptor Inhibition. Eur J Biochem 1994; 225: 21–27.
113. Siller-Matula JM, et al. Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay. Platelets 2008; 19: 551–554.
114. Aleil B, et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85–92.
115. Geiger J, et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999; 19: 2007–2011.
116. Dropinski J, et al. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. Thromb Haemost 2007; 98: 201–209.
117. Cuisset T, et al. Clopidogrel resistance: What’s new? Arch Cardiovasc Dis 2010; 103: 349–353.
118. Bonello L, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postpro-cedural major adverse cardiovascular events. J Thromb Haemost 2007; 5: 1630–1636.
119. Jakubowski JA, et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2008; 99: 215–222.
120. Frere C, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838–843.
121. Stimpfle F, Geisler T. Impact of tailored anti-P2Y12 therapies in acute coronary syndromes. Pharmacogenomics 2015; 16: 493–499.
122. Hazarbasanov D, et al. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. J Thromb Thrombolysis 2012; 34: 85–90.
123. Hayward CPM, et al. Development of North American Consensus Guidelines for Medical Laboratories That Perform and Interpret Platelet Function Testing Using Light Transmission Aggregometry. Am J Clin Pathol 2010; 134: 955–963.
124. Breet NJ, et al. COmparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754–762.
125. Tantry US, et al. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. J Am Coll Cardiol 2013; 62: 2261–2273.
126. Aradi D, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014; 35: 209–215.
127. Mobley JE, et al. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterisation. Am J Cardiol 2004; 93: 456–458.
128. Harrison P, et al. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007; 120: 323–336.
129. Bonello L, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919–933.